secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001193805-23-000241
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic reports FY2022 net loss of $120.4M; cash $116.4M; goodwill impairment $33M
--------------------------------------------------------------------------------

- Net loss $120.4M ($3.78/share) vs $92.9M ($3.93/share) in 2021; R&D expenses $71.3M.
- Recorded non-cash goodwill impairment of $33M in Q4 2022 due to stock price decline after izumerogant psoriasis data.
- Cash, equivalents and investments $116.4M as of Dec 31, 2022; expected to fund operations into Q4 2024.
- Clinical milestones: IMU-856 celiac data mid-2023; CALLIPER progressive MS interim H2 2023; ENSURE relapsing MS interim late 2024.
- Closed $60M private placement in Oct 2022 with new and existing institutional investors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380523000241/0001193805-23-000241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380523000241/e618296_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-000241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer